These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32349656)

  • 1. Predicting potential adverse events using safety data from marketed drugs.
    Daluwatte C; Schotland P; Strauss DG; Burkhart KK; Racz R
    BMC Bioinformatics; 2020 Apr; 21(1):163. PubMed ID: 32349656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting.
    Schotland P; Racz R; Jackson DB; Soldatos TG; Levin R; Strauss DG; Burkhart K
    Clin Pharmacol Ther; 2021 May; 109(5):1232-1243. PubMed ID: 33090463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS).
    Xu R; Wang Q
    J Biomed Inform; 2014 Feb; 47():171-7. PubMed ID: 24177320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generalized enrichment analysis improves the detection of adverse drug events from the biomedical literature.
    Winnenburg R; Shah NH
    BMC Bioinformatics; 2016 Jun; 17():250. PubMed ID: 27333889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilizing Deep Learning for Detecting Adverse Drug Events in Structured and Unstructured Regulatory Drug Data Sets.
    Knisely BM; Hatim Q; Vaughn-Cooke M
    Pharmaceut Med; 2022 Oct; 36(5):307-317. PubMed ID: 35871475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
    Szarfman A; Machado SG; O'Neill RT
    Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.
    Hauben M; Horn S; Reich L
    Drug Saf; 2007; 30(2):143-55. PubMed ID: 17253879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilizing drug-target-event relationships to unveil safety patterns in pharmacovigilance.
    Hauser AS; Kooistra AJ; Sverrisdóttir E; Sessa M
    Expert Opin Drug Saf; 2020 Aug; 19(8):961-968. PubMed ID: 32510245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports.
    Liu R; Zhang P
    BMC Med Inform Decis Mak; 2019 Dec; 19(1):279. PubMed ID: 31849321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts.
    Pierce CE; Bouri K; Pamer C; Proestel S; Rodriguez HW; Van Le H; Freifeld CC; Brownstein JS; Walderhaug M; Edwards IR; Dasgupta N
    Drug Saf; 2017 Apr; 40(4):317-331. PubMed ID: 28044249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of three methods (consensual expert judgement, algorithmic and probabilistic approaches) of causality assessment of adverse drug reactions: an assessment using reports made to a French pharmacovigilance centre.
    Théophile H; Arimone Y; Miremont-Salamé G; Moore N; Fourrier-Réglat A; Haramburu F; Bégaud B
    Drug Saf; 2010 Nov; 33(11):1045-54. PubMed ID: 20925441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of three signal-detection algorithms using a highly inclusive reference event database.
    Hochberg AM; Hauben M; Pearson RK; O'Hara DJ; Reisinger SJ; Goldsmith DI; Gould AL; Madigan D
    Drug Saf; 2009; 32(6):509-25. PubMed ID: 19459718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
    Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
    J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A chronological pharmacovigilance network analytics approach for predicting adverse drug events.
    Davazdahemami B; Delen D
    J Am Med Inform Assoc; 2018 Oct; 25(10):1311-1321. PubMed ID: 30085102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the detection, reporting and investigation of adverse events in clinical trial protocols implemented in Cameroon: a documentary review of clinical trial protocols.
    Ebile AW; Ateudjieu J; Yakum MN; Djuidje MN; Watcho P
    BMC Med Ethics; 2015 Sep; 16(1):67. PubMed ID: 26420169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comparison Study of Algorithms to Detect Drug-Adverse Event Associations: Frequentist, Bayesian, and Machine-Learning Approaches.
    Pham M; Cheng F; Ramachandran K
    Drug Saf; 2019 Jun; 42(6):743-750. PubMed ID: 30762164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data-driven prediction of adverse drug reactions induced by drug-drug interactions.
    Liu R; AbdulHameed MDM; Kumar K; Yu X; Wallqvist A; Reifman J
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):44. PubMed ID: 28595649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of three methods (an updated logistic probabilistic method, the Naranjo and Liverpool algorithms) for the evaluation of routine pharmacovigilance case reports using consensual expert judgement as reference.
    Théophile H; André M; Miremont-Salamé G; Arimone Y; Bégaud B
    Drug Saf; 2013 Oct; 36(10):1033-44. PubMed ID: 23828659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.